Nargenicin A1 is an antibiotic against Gram-positive bacteria, particularly Staphylococcus and Clostridia. It is more effective against multi-resistan strains(MRSA) than erythromycin and vancomycin. But it shows low cytotoxicity compared to erythromycin and spiramycin. Nargenicin A1 inhibits cell proliferation and induces HL-60 cell differentiation in combination with 1,25-Dihydroxyvitamin-D3 and ATRA.
Product Rerences
Effect of different biosynthetic precursors on the production of nargenicin A1 from metabolically engineered Nocardia sp. CS682., Koju D, et al,?J Microbiol Biotechnol.,?22(8):1127-32 (2012)
Nargenicin enhances 1,25-dihydroxyvitamin D(3)- and all-trans retinoic acid-induced leukemia cell differentiation via PKCbetaI/MAPK pathways., Kim SH, et al,?Biochem Pharmacol.,?77(11):1694-701 (2009)
Nargenicin attenuates lipopolysaccharide-induced inflammatory responses in BV-2 cells, Yoo JC, et al, Neuroreport, 20(11):1007-12 (2009)
BIOLEAF熱搜 BIOLEAF試劑盒 BIOLEAF ELISA BIOLEAF試劑 BIOLEAF品牌 BIOLEAF抗體 BIOLEAF耗材 BIOLEAF小儀器
sitemap 細胞庫查詢 危險品圖標 本公司網(wǎng)站所展示銷售的產(chǎn)品僅供科研！
滬公網(wǎng)安備 31011202007338號
